Back to results
US 2019/0316124 A1Published application
Semaphorin 3d and plexin d1 as therapeutic targets for pancreatic cancer treatment
AssigneeThe Johns Hopkins University
InventorLei Zheng
Life of this patent
Estimating the term…
Abstract
The invention features compositions and methods for treating and preventing pancreatic cancer.
Claims24
A method of reducing or inhibiting tumor invasion or tumor metastatic progression in a subject comprising:
- identifying a subject having or at risk of developing cancer;
- and
- administering to the subject an effective amount of an agent that reduces the transcription or activity of Semaphorin,
- thereby reducing or inhibiting tumor invasion or tumor metastatic progression in said subject.
1 more element
The method of claim 19, wherein said agent that reduces the transcription or activity of Sema3D and said agent that reduces the transcription or activity of PlxnD1 are administered twice per week.
A method of screening for a candidate compound which inhibits tumor invasion and/or tumor metastasis, comprising:
- contacting a candidate compound with a pancreatic cancer cell;
- determining a Sema3D secretion level;
- and
- identifying the candidate compound as a candidate compound for inhibiting tumor invasion and/or tumor metastasis if the candidate compound inhibits secretion of Sema3D.
1 more element
A method of determining whether pancreatic cancer will metastasize in a subject comprising
- obtaining a pancreatic tumor sample from a subject;
- determining a level of Sema3D in said tumor sample;
- comparing said level of Sema3D in said tumor sample to a control level of Sema3D, wherein an increased level of Sema3D in said tumor sample relative to the control level of Sema3D indicates said pancreatic cancer will metastasize in said subject.
Dependencies are inferred from the claim text.